The firm said it anticipates using the financing to support working capital requirements, platform development, and pilot manufacturing.
The Swedish company is developing sequencing- and PCR-based tests and services that quantify aberrations in DNA, RNA, and circulating tumor DNA.
The funds will support Curetis' R&D efforts, which include partnering its Unyvero A30 RQ mid-plex diagnostics system for verification and validation testing.
The direct-to-consumer at-home health testing firm intends to use the funds to expands its platform development and supply logistics in North America.
The financing accelerates the development of the Zero Delay plasma preparation system for immediate blood plasma isolation and stabilization at the point of collection.
The Canadian company said it will use the funding to support the US launch of its rapid, noninvasive test for platelet activation status.
The funding will be available in seven tranches, including an initial €2.0 million tranche of bonds with warrants that the company immediately exercised.
BrightEdge was founded by the American Cancer Society to invest in for-profit companies developing novel cancer therapeutics and diagnostics.
The Boston-based company said it will use the funding in part to continue refining its artificial intelligence-powered pathology research platform.
The Austin, Texas-based company offers more than 30 tests, including those for food sensitivity, fertility and women's hormones, sexually transmitted diseases, and thyroid.